Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Herceptin license extended

  • Comment
Trastuzumab (Herceptin) used in combination with an aromatase inhibitor has been approved for use in the treatment of an aggressive form of breast cancer.

Trastuzumab (Herceptin) used in combination with an aromatase inhibitor has been approved for use in the treatment of an aggressive form of breast cancer.

Trial data showed adding trastuzumabto hormonal therapy doubled survival times in postmenopausal patients with HER2 and hormone receptor co-positive metastatic breast cancer. The median progression-free survival time from 2.4 months to 4.8 months.

William Burns, chief executiveof Roche Pharmaceuticals, which produces the drug, said: 'For the first time a combination of targeted therapies is available for patients who suffer from a particularly aggressive form of breast cancer.'

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.